OBI Pharma Gestion

Gestion contrôle des critères 1/4

Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.

Informations clés

Heidi Wang

Directeur général

n/a

Rémunération totale

Pourcentage du salaire du PDG	n/a
Durée du mandat du directeur général	1.4yrs
Propriété du PDG	n/a
Durée moyenne d'occupation des postes de direction	2.8yrs
Durée moyenne du mandat des membres du conseil d'administration	2.4yrs

Mises à jour récentes de la gestion

Recent updates

OBI Pharma (GTSM:4174) Shareholders Booked A 69% Gain In The Last Year

Mar 12

Here's Why OBI Pharma (GTSM:4174) Can Manage Its Debt Despite Losing Money

Jan 18

If You Had Bought OBI Pharma's (GTSM:4174) Shares Five Years Ago You Would Be Down 82%

Nov 26

PDG

Heidi Wang

1.4yrs

Titularisation

Dr. Heidi Wang, Ph D., is Chief Executive Officer of OBI Pharma, Inc. from June 2023. Dr. Wang joined the OBI Pharma, Inc. in June 2023.She brings a wealth of global executive management, scientific know...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Ming-Tain Lai	Chief Scientific Officer	5.2yrs	NT$7.73m	0.0044% NT$ 629.7k
Heidi Wang	Chief Executive Officer	1.4yrs	pas de données	pas de données
Colin Kao	CFO, Accounting Supervisor & Corporate Governance Supervisor	1.7yrs	pas de données	pas de données
Po-Jen Chang	Director of Human Resources & Administration	3.9yrs	pas de données	pas de données
Sharon Lee	Director of Public Affairs	8.7yrs	pas de données	pas de données
Kevin P. Poulos	Chief Business Officer of OBI Pharma USA	11.8yrs	pas de données	pas de données
Wayne Saville	Chief Medical Officer of OBI Pharma USA	2.8yrs	pas de données	pas de données
Dong Xu	Senior Vice President of Biostatistics & Data Management of OBI Pharma USA	less than a year	pas de données	pas de données
Chun-Hung Chou	Vice President of Chemical Pharmacy and R&D Office	2.6yrs	pas de données	0.00044% NT$ 63.5k

2.8yrs

Durée moyenne de l'emploi

Gestion expérimentée: L'équipe de direction de 4174 est considérée comme expérimentée (ancienneté moyenne 2.8 ans).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Ming-Chin Chen	Independent Director	2.4yrs	NT$340.00k	pas de données
Tamon Tseng	Director	8.4yrs	NT$25.00k	pas de données
Howard S. Lee	Independent Director	3.3yrs	NT$660.00k	pas de données
Chin-Ting Chiu	Independent Director	2.4yrs	NT$340.00k	pas de données
Wan-Fang Ting	Director	1.3yrs	pas de données	pas de données
Kung-Yee Liang	Chairman	less than a year	pas de données	pas de données

2.4yrs

Durée moyenne de l'emploi

Conseil d'administration expérimenté: Le conseil d'administration de la 4174 n'est pas considéré comme expérimenté ( 2.4 années d'ancienneté moyenne), ce qui suggère un nouveau conseil d'administration.

OBI Pharma Gestion

Gestion contrôle des critères 1/4

Informations clés

Mises à jour récentes de la gestion

OBI Pharma, Inc. Announces Resignation of Yun Yen as Chairperson and Director, Effective December 29, 2023

OBI Pharma, Inc. Announces CFO Changes

OBI Pharma, Inc. Announces CFO Changes

Less than half of directors are independent

OBI Pharma, Inc. Announces Appointment of Yun Yen as the Chairman

OBI Pharma, Inc. Announces Appointment of Yun Yen as Natural-Person Director

Recent updates

Third quarter 2024 earnings released: NT$2.27 loss per share (vs NT$2.48 loss in 3Q 2023)

OBI Pharma, Inc. to Report Q3, 2024 Results on Nov 04, 2024

Second quarter 2024 earnings released: NT$2.36 loss per share (vs NT$1.79 profit in 2Q 2023)

OBI Pharma, Inc. to Report Q2, 2024 Results on Aug 02, 2024

OBI Pharma, Inc. Files the Application of Phase I/II human clinical trial for OBI-992 TROP2 ADC to TFDA

New major risk - Financial position

OBI Pharma, Inc. to Report Q1, 2024 Results on May 10, 2024

Full year 2023 earnings released: NT$4.57 loss per share (vs NT$7.27 loss in FY 2022)

Obi Pharma, Inc. Announces the Termination of Obi-3424-001 Trial While Continuing the Collaboration Of obi-3424 with Partners

OBI Pharma, Inc. Announces Adagloxad Simolenin (OBI-822) Receives Positive 1st Interim Analysis Recommendation, Recommending the Continues of the Phase III TNBC Trial

OBI Pharma, Inc. Announces Resignation of Yun Yen as Chairperson and Director, Effective December 29, 2023

Obi Pharma, Inc. Files the Application of Phase I/II Human Clinical Trial for OBI-992 TROP2 ADC to US FDA

OBI Pharma, Inc. Announces CFO Changes

OBI Pharma, Inc. Announces CFO Changes

Less than half of directors are independent

Second quarter 2023 earnings released: EPS: NT$1.79 (vs NT$1.50 loss in 2Q 2022)

OBI Pharma, Inc. Announces Appointment of Yun Yen as the Chairman

OBI Pharma, Inc. Announces Appointment of Yun Yen as Natural-Person Director

OBI Pharma, Inc. Announces COVID-19 Vaccine, BCVax, Has Been Granted by TFDA to Proceed to Phase I Clinical Trial

OBI Pharma Appoints Heidi Wang as Chief Executive Officer

Full year 2022 earnings released: NT$7.27 loss per share (vs NT$7.69 loss in FY 2021)

Obi Pharma, Inc. Files Application for Phase II Human Clinical Trial of First-In-Class Novel Prodrug, Obi-3424, to TFDA

OBI Pharma, Inc. Announces Demise of Chairman of the Board, Michael Chang

Less than half of directors are independent

Second quarter 2022 earnings released: NT$1.50 loss per share (vs NT$2.09 loss in 2Q 2021)

OBI Pharma, Inc. announced that it expects to receive TWD 800 million in funding

Obi Pharma Announces Discontinuation of the Phase 1/2 Study of Iis Antibody- OBI 888

OBI Pharma, Inc. Announces Audit Committee Changes

First quarter 2022 earnings released: NT$1.52 loss per share (vs NT$1.16 loss in 1Q 2021)

Less than half of directors are independent

OBI Pharma, Inc. Announces That AEMPS of Spain Revokes Previous Approval for the Active Cancer Immunotherapy, OBI-822, to Proceed to Phase III Clinical Trial

Full year 2021 earnings released: NT$7.69 loss per share (vs NT$7.34 loss in FY 2020)

OBI Pharma, Inc. Announces TFDA Grants Approval for Active Cancer Immunotherapy OBI-833 to Proceed to Phase II Clinical Trial

OBI Pharma, Inc. Announces Preliminary Findings of Their In-House Developed Next-Generation COVID-19 Vaccine, BCVax

OBI Pharma, Inc. Announces Phase 2 Studies Patient Enrollment for Obi-999 and Obi-3424

Directorate General of Drug Supplies and Drugs of Peru Grants OBI Pharma, Inc.'s OBI-822 (Adagloxad Simolenin) to Proceed to Phase III Clinical Trial

OBI Files the Application for Phase II clinical Trial for Obi-833, an Active Cancer immunotherapy, to TFDA

Third quarter 2021 earnings released: NT$1.64 loss per share (vs NT$2.02 loss in 3Q 2020)

Second quarter 2021 earnings released: NT$2.09 loss per share (vs NT$1.67 loss in 2Q 2020)

First quarter 2021 earnings released: NT$1.16 loss per share (vs NT$1.67 loss in 1Q 2020)

OBI Pharma, Inc. Announces First Patient Enrolled on SWOG Cancer Research Network's OBI-3424 Phase 1/2 Study Targeting AKR1C3 in T-ALL and T-LBL

Full year 2020 earnings released: NT$7.34 loss per share (vs NT$7.76 loss in FY 2019)

OBI Pharma, Inc., Annual General Meeting, Jun 21, 2021

OBI Pharma (GTSM:4174) Shareholders Booked A 69% Gain In The Last Year

New 90-day high: NT$153

Here's Why OBI Pharma (GTSM:4174) Can Manage Its Debt Despite Losing Money

New 90-day high: NT$124

If You Had Bought OBI Pharma's (GTSM:4174) Shares Five Years Ago You Would Be Down 82%

OBI Pharma, Inc. Announces Presentation of Data from the OBI-833 Phase 1 Clinical Study at European Society of Clinical Oncology Asia 2020 Virtual Scientific Program

Third quarter 2020 earnings released: NT$2.02 loss per share

New 90-day low: NT$108

Price target lowered to NT$148

First half earnings released

PDG

Titularisation

Équipe de direction

Durée moyenne de l'emploi

Membres du conseil d'administration

Durée moyenne de l'emploi